[1]雷画星.加味二陈汤联合化疗治疗非小细胞肺癌的效果观察[J].医学信息,2024,37(02):132-135.[doi:10.3969/j.issn.1006-1959.2024.02.026]
　LEI Hua-xing.Effect Observation of Jiawei Erchen Decoction Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer[J].Journal of Medical Information,2024,37(02):132-135.[doi:10.3969/j.issn.1006-1959.2024.02.026]
点击复制

加味二陈汤联合化疗治疗非小细胞肺癌的效果观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年02期
页码:
132-135
栏目:
论著
出版日期:
2024-01-15

文章信息/Info

Title:
Effect Observation of Jiawei Erchen Decoction Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer
文章编号:
1006-1959（2024）02-0132-04
作者:
雷画星
（余干县人民医院肿瘤科，江西 余干 335103）
Author(s):
LEI Hua-xing
(Department of Oncology,Yugan County People’s Hospital,Yugan 335103,Jiangxi,China)
关键词:
非小细胞肺癌; 加味二陈汤; 生存质量; 肿瘤标志物
Keywords:
Non-small cell lung cancer; Jiawei Erchen decoction; Quality of life; Tumor markers
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2024.02.026
文献标志码:
A
摘要:
目的 研究加味二陈汤联合化疗治疗非小细胞肺癌（NSCLC）患者的临床效果。方法 选取2019年3月-2022年3月余干县人民医院肿瘤科收治的62例NSCLC患者，按照随机数字表法分为对照组（31例）与观察组（31例）。对照组行化疗治疗，观察组在其基础上联合加味二陈汤治疗。比较两组近期疗效、中医症状积分、肿瘤标志物水平[癌胚抗原（CEA）、鳞状细胞癌相关抗原（SCC）]、不良反应、Karnofsky功能状态量表（KPS）评分、肺癌患者生存质量测定量表（FACT-L）评分。结果 观察组疾病控制率、客观缓解率高于对照组（P＜0.05）；两组治疗后中医症状积分均小于治疗前，且观察组中医症状积分小于对照组（P＜0.05）；两组治疗后CEA、SCC水平低于治疗前，且观察组CEA、SCC水平低于对照组（P＜0.05）；两组治疗后KPS、FACT-L评分高于治疗前，且观察组KPS、FACT-L评分高于对照组（P＜0.05）；观察组不良反应发生率小于对照组（P＜0.05）。结论 加味二陈汤联合化疗治疗NSCLC近期疗效理想，可进一步减轻患者症状，下调其肿瘤标志物水平，减少药物不良反应，有助于改善患者健康状况及生存质量。
Abstract:
Objective To study the clinical effect of Jiawei Erchen decoction combined with chemotherapy in the treatment of patients with non-small cell lung cancer (NSCLC).Methods A total of 62 patients with NSCLC admitted to the Department of Oncology, Yugan County People’s Hospital from March 2019 to March 2022 were selected and divided into control group (31 patients) and observation group (31 patients) according to the random number table method. The control group was treated with chemotherapy, and the observation group was treated with Jiawei Erchen decoction on the basis of the control group. The short-term efficacy, TCM symptom score, tumor marker levels [carcinoembryonic antigen (CEA), squamous cell carcinoma-associated antigen (SCC)], adverse reactions, Karnofky Performance Status (KPS) score, and Functional Assessment of Cancer Therapy-Lung (FACT-L) scale score were compared between the two groups.Results The disease control rate and objective remission rate of the observation group were higher than those of the control group (P<0.05). After treatment, the scores of TCM symptoms in the two groups were lower than those before treatment, and the scores of TCM symptoms in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of CEA and SCC in the two groups were lower than those before treatment, and the levels of CEA and SCC in the observation group were lower than those in the control group (P<0.05). The KPS and FACT-L scores of the two groups after treatment were higher than those before treatment, and the KPS and FACT-L scores of the observation group were higher than those of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).Conclusion Jiawei Erchen decoction combined with chemotherapy has an ideal short-term effect in the treatment of NSCLC, which can further alleviate the symptoms of patients, down-regulate the level of tumor markers, reduce adverse drug reactions, and help to improve the health status and quality of life of patients.

参考文献/References:

[1]谭明娜,胡芳,李国斌,等.加味人参养荣汤联合GP方案对气血亏虚型晚期非小细胞肺癌患者的临床疗效[J].中成药,2021,43(7):1763-1767.[2]迟文成,牛泽基,姜家康,等.六君子汤加味治疗非小细胞肺癌化疗后白细胞减少症的有效性分析[J].中医药学报,2022,50(5):76-79.[3]高海利,吴晋芳,陈尧,等.下气汤对中晚期非小细胞肺癌癌因性疲乏的防治作用研究[J].广州中医药大学学报,2022,39(4):769-775.[4]千维娜,李治,李仁廷,等.益气养阴方联合TP化疗方案治疗非小细胞肺癌气阴两虚证[J].中医学报,2021,36(4):869-874.[5]王群,王水英,王燕,等.培土补肺汤用于非小细胞肺癌患者化疗期增效减毒作用观察[J].四川中医,2021,39(12):92-95.[6]旋静,孙文哲,李岫,等.补肺化积汤治疗晚期非小细胞肺癌[J].长春中医药大学学报,2021,37(6):1286-1288.[7]丁倩,李亚玲,王莉娟,等.CIK细胞联合加味二陈汤治疗化疗耐药的晚期NSCLC的临床研究[J].西南国防医药,2018,28(10):901-903.[8]李晶,徐鸿飞,许超.二陈汤辅助化疗对痰湿证非小细胞肺癌患者的临床疗效及对T淋巴细胞亚群的影响[J].中药材,2019,42(11):2706-2708.[9]中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华肿瘤杂志,2021,43(6):591-621.[10]王学谦,侯炜,郑佳彬,等.中医综合治疗方案维持治疗晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究[J].中医杂志,2020,61(8):690-694.[11]黄念,王紫阳.解氏肺癌三号方在非小细胞肺癌患者放化疗治疗中的应用及对血清肿瘤标记物、放疗毒副反应的影响[J].四川中医,2020,38(4):97-100.[12]Kobayashi K,Seike M,Zou F,et al.Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression[J].Anticancer Research,2018,38(2):753-762.[13]岳斌,何晓华,李占林.加味金水六君煎对非小细胞肺癌患者化疗后T淋巴细胞亚群的影响[J].中国中医基础医学杂志,2018,24(3):358-360,369.[14]谷志彬,刘玲莉.中西医结合治疗晚期非小细胞肺癌患者的效果[J].实用临床医药杂志,2019,23(9):13-15,19.[15]马思遥.中医辨证治疗联合GP化疗方案对非小细胞肺癌的疗效及对免疫功能的影响[J].辽宁中医杂志,2022,49(7):102-105.[16]谢国群,翁诗婷,钱鹏.二陈汤辅助NP化疗方案辨证治疗痰证非小细胞肺癌的临床观察[J].辽宁中医杂志,2018,45(4):738-741.[17]周舟,张英,董军,等.中医药预防非小细胞肺癌术后复发转移优势患者的中医学特征[J].中国中医药信息杂志,2019,26(1):23-26.[18]王萍,姬生威,万鸿,等.汤剂联合化疗对老年晚期非小细胞肺癌的疗效[J].国际老年医学杂志,2020,41(4):219-222.[19]辛晓丽,姜怡,沈丽萍,等.中医药辅助治疗600例老年非小细胞肺癌患者的生存分析[J].中医杂志,2019,60(1):31-35,46.[20]单孟俊,张丽媛,游捷.中医辨证疗法联合化疗治疗老年晚期非小细胞肺癌患者随机对照研究[J].中国中西医结合杂志,2018,38(2):163-167.[21]宋丽君,马雪娇,郑佳彬,等.中医综合方案联合化疗治疗Ⅳ期非小细胞肺癌的多中心随机对照研究[J].北京中医药,2022,41(1):2-6.[22]焦丽静,李嘉旗,龚亚斌,等.中医药联合辅助化疗对早期非小细胞肺癌术后患者舌象变化规律的影响[J].上海中医药杂志,2020,54(2):21-27.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(02):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(02):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(02):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(02):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01